Companies: Merck & Co., AstraZeneca, Daiichi Sankyo
Drugs: datopotamab deruxtecan, Keytruda, Dato-DXd, docetaxel
MSD MRK AZN
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint
100% citation coverage2 regulatory sources
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan met the dual primary endpoint of progression-free survival in TROPION-Lung01, strengthening the program’s clinical case in advanced NSCLC. The readout matters for investors and BD teams because it arrives alongside an FDA-labeled EGFR-mutated NSCLC indication and a mixed breast cancer survival backdrop.
Intelligence Snapshot
Executive Summary
Datopotamab deruxtecan met the dual primary endpoint of progression-free survival in TROPION-Lung01 for patients with advanced non-small cell lung cancer .
Key Insights
-
The drug demonstrated a median overall survival of 14.6 months in patients with advanced…
The drug demonstrated a median overall survival of 14.6 months in patients with advanced nonsquamous NSCLC in the phase III trial.
-
DATROWAY is FDA-indicated for EGFR-mutated NSCLC after prior EGFR-directed therapy and…
DATROWAY is FDA-indicated for EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy under accelerated approval.
- TROPION-Breast01 overall survival results did not achieve statistical significance.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Loading intelligence…
Loading intelligence…
Loading intelligence…
Loading intelligence…
Quick Answer
Datopotamab deruxtecan met the dual primary endpoint of progression-free survival in TROPION-Lung01 for patients with advanced non-small cell lung cancer .
Key Questions
- What changed with the TROPION-Lung01 readout?
- Who is affected by this result?
- What should pharma teams watch next?
- How does the current FDA label define the patient population?
- Why did TROPION-Breast01 miss its overall survival endpoint?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for datopotamab deruxtecan.
Unlock full calendar →Merck & Co. pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Contents15 sections
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan meets dual primary endpoint in TROPION-Lung01
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan met the dual primary endpoint of progression-free survival in TROPION-Lung01, strengthening the program's clinical case in advanced NSCLC. The readout matters for investors and BD teams because it arrives alongside an FDA-labeled EGFR-mutated NSCLC indication and a mixed breast cancer survival backdrop from TROPION-Breast01.
IntelligenceRegulatory Impact
FDA and EMA decisions frame this story. Regulatory relevance is high for oncology, with datopotamab deruxtecan and Keytruda most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key Takeaways
- Datopotamab deruxtecan met the dual primary endpoint of progression-free survival in TROPION-Lung01 for patients with advanced non-small cell lung cancer.
- The drug demonstrated a median overall survival of 14.6 months in patients with advanced nonsquamous NSCLC in the phase III trial.
- DATROWAY is FDA-indicated for EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy under accelerated approval.
- TROPION-Breast01 overall survival results did not achieve statistical significance.
IntelligenceCompetitive Intelligence
Merck & Co., AstraZeneca, and Daiichi Sankyo are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.
TROPION-Lung01 establishes the core clinical signal
Datopotamab deruxtecan met the dual primary endpoint of progression-free survival in the TROPION-Lung01 trial for patients with advanced non-small cell lung cancer. This phase III readout anchors the clinical profile for the asset in the advanced NSCLC setting.
The clinical foundation extends beyond the primary endpoint. Datopotamab deruxtecan showed a median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in the TROPION-Lung01 phase III trial. For BD teams and investors, this survival readout is a key data point for the asset's clinical profile in the advanced NSCLC setting.
The trial was a global, randomized phase III study design. The focus on the nonsquamous population reflects a defined patient cohort within the broader advanced NSCLC landscape.
IntelligenceMarket Signals
Commercial pull is high and investment relevance high for oncology. Expect implications for pricing, access, and launch sequencing.
FDA label defines the current commercial footing
Datopotamab deruxtecan is indicated for adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who have received prior EGFR-directed therapy and platinum-based chemotherapy. The branded product, DATROWAY, carries this indication under accelerated approval.
Accelerated approval status means the label is contingent on verification of clinical benefit in a confirmatory trial. The current indication targets a defined patient population—those with documented EGFR mutations who have progressed through both targeted therapy and chemotherapy.
The route of administration is intravenous, consistent with other antibody-drug conjugates in oncology. Manufacturing and supply-chain readiness become operational considerations as commercial execution proceeds.
IntelligenceStrategic Takeaways
Datopotamab deruxtecan met the dual primary endpoint of progression-free survival in TROPION-Lung01 for patients with advanced non-small cell lung cancer . The drug demonstrated a median overall survival of 14.6 months in patients with advanced nonsquamous NSCLC in the phase III trial. DATROWAY is FDA-indicated for EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy under accelerated
TROPION-Lung05 and related studies in the pipeline
The TROPION-Lung05 phase II trial evaluated the safety and clinical activity of Dato-DXd in patients with advanced or metastatic non-small cell lung cancer with actionable genomic alterations.
Beyond TROPION-Lung05, the development pipeline includes multiple recruiting trials. A phase III study is evaluating datopotamab deruxtecan versus docetaxel in previously treated TROP2-positive advanced or metastatic non-squamous NSCLC without actionable genomic alterations, directly addressing a population outside the current EGFR-mutated label.
A phase II study in neoadjuvant and adjuvant treatment in resectable non-small cell lung cancer is also recruiting. A phase III, randomized study of adjuvant Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy versus standard of care in participants with stage I adenocarcinoma NSCLC who are ctDNA-positive or have high-risk pathological features is active but not recruiting.
IntelligenceEvidence Quality
Grounded in 2 regulatory sources.
Breast readthrough and cross-program interpretation
The TROPION-Breast01 trial results for datopotamab deruxtecan did not achieve statistical significance for overall survival, a setback in the triple-negative breast cancer indication.
This divergence between lung and breast outcomes is instructive for pharma teams evaluating Dato-DXd as a program asset. Lung cancer and breast cancer represent distinct tumor microenvironments and patient populations. The PFS win in lung does not erase the breast outcome, but it does highlight that clinical activity may vary across indications depending on tumor type and prior treatment history.
What to watch next
The TROPION-Lung01 PFS endpoint achievement creates several data catalysts to monitor. The next major readout is the phase III study of datopotamab deruxtecan versus docetaxel in TROP2-positive advanced or metastatic non-squamous NSCLC without actionable genomic alterations.
Pharma teams should also track the status of the phase II study evaluating datopotamab deruxtecan plus durvalumab versus datopotamab deruxtecan in patients with PDL1-negative metastatic triple-negative breast cancer. Regulatory filings and label updates based on TROPION-Lung01 data represent additional catalysts to monitor.
Drug Snapshot
| Drug | datopotamab deruxtecan |
|---|---|
| Generic name | DATOPOTAMAB DERUXTECAN |
| Manufacturer | Daiichi Sankyo Inc. |
| Route | INTRAVENOUS |
| Indication | 1 INDICATIONS AND USAGE DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. ( 1.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinic |
Regulatory Summary
- Approved indication: 1 INDICATIONS AND USAGE DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. ( 1.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinic
- Daiichi Sankyo Inc. develops datopotamab deruxtecan
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT05417594 | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | RECRUITING | PHASE1, PHASE2 | AstraZeneca |
| NCT07291037 | Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations | RECRUITING | PHASE3 | AstraZeneca |
| NCT05061550 | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer | RECRUITING | PHASE2 | AstraZeneca |
| NCT06954480 | Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer | RECRUITING | PHASE2 | Queen Mary University of London |
| NCT06564844 | A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features | ACTIVE_NOT_RECRUITING | PHASE3 | AstraZeneca |
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| National Cancer Institute (NCI) | oncology | 2 |
| National Institute of Dental and Craniofacial Research (NIDCR) | oncology | 1 |
| Janssen Research & Development, LLC | oncology | 1 |
| Arsenal Biosciences, Inc. | oncology | 1 |
| Regina Elena Cancer Institute | oncology | 1 |
| Aragon Pharmaceuticals, Inc. | oncology | 1 |
Timeline
- Recruiting trial NCT05417594 (PHASE1, PHASE2)
- Recruiting trial NCT07291037 (PHASE3)
- Recruiting trial NCT05061550 (PHASE2)
- Recruiting trial NCT06954480 (PHASE2)
- Active_Not_Recruiting trial NCT06564844 (PHASE3)
Frequently Asked Questions
What changed with the TROPION-Lung01 readout?
Datopotamab deruxtecan met the dual primary progression-free survival endpoint in the TROPION-Lung01 phase III trial for advanced non-small cell lung cancer. The drug showed a median overall survival of 14.6 months in patients with advanced nonsquamous NSCLC.
Who is affected by this result?
AstraZeneca and Daiichi Sankyo are the primary stakeholders, along with BD teams, investors, and analysts following the Dato-DXd lung cancer program. Patients with EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy represent the current labeled population.
What should pharma teams watch next?
Monitor the readout of the phase III trial evaluating datopotamab deruxtecan versus docetaxel in TROP2-positive advanced or metastatic non-squamous NSCLC without actionable genomic alterations. Track regulatory filings and label updates based on TROPION-Lung01 data. Follow the status of the phase II study in neoadjuvant and adjuvant treatment in resectable non-small cell lung cancer and the phase III adjuvant study in stage I adenocarcinoma NSCLC.
How does the current FDA label define the patient population?
The current indication is restricted to EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy. Ongoing phase III trials are evaluating datopotamab deruxtecan in broader NSCLC populations, particularly those with TROP2 positivity but without EGFR mutations.
Why did TROPION-Breast01 miss its overall survival endpoint?
TROPION-Breast01 results for datopotamab deruxtecan did not achieve statistical significance for overall survival. This outcome in triple-negative breast cancer contrasts with the PFS win in lung cancer, indicating that clinical activity may vary across indications.
What other NSCLC trials are active or recruiting?
A phase II study in neoadjuvant and adjuvant treatment in resectable non-small cell lung cancer is recruiting. A phase III, randomized study of adjuvant Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy versus standard of care in participants with stage I adenocarcinoma NSCLC who are ctDNA-positive or have high-risk pathological features is active but not recruiting. These trials expand the development scope beyond advanced disease.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About oncology
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow datopotamab deruxtecan developments
FDA oncology alerts and datopotamab deruxtecan pipeline updates, every Monday.
- Sources analyzed
- 2
- Evidence strength
- 96/100
- Last verified
- Jun 7, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Critical source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
About the Author
Continue Your Research
Industry Reports & Whitepapers
- RYBREVANT® Access and Reimbursement Guide Overview — Explore key insights on RYBREVANT® reimbursement and access strategies for NSCLC treatment.…
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…